BPC-157 vs TB-500: comparing two compounds with no human evidence

Comparing two unknowns

These two get discussed as a pair constantly, and sold as a pair almost as often. The question is always which is better for healing.

Neither has adequate randomized human evidence, so the question has no answer.

That's an unsatisfying place to start and it's the honest one. Here's what separates them on the things we can actually establish.

Ratings from our research directory. Prices from our price market, checked 25 July 2026.

TB-500's specific problem: it isn't the molecule that was studied

This is the single most useful thing on this page, and it's rarely stated plainly.

TB-500 is a fragment. A synthetic acetylated seven-amino-acid sequence corresponding to residues 17 through 23 of thymosin beta-4.

Thymosin beta-4 is the full protein, and it has genuinely been studied in humans, including ophthalmic formulations such as RGN-259.

Those studies are not evidence for TB-500.

A seven-residue fragment and the full-length protein are different molecules with different behaviour in the body. Citing research on one to support claims about the other is the substitution that most TB-500 marketing depends on, and once you see it you'll notice it everywhere.

Our profile is direct about the regulatory picture too: the FDA found no identified human exposure data for drug products containing the TB-500 fragment.¹

Read that carefully. Not "limited data." No identified human exposure data.

BPC-157's problem is simpler

No borrowed-evidence issue here. The research is about the right molecule, and there just isn't enough of it in people.

There is no adequate randomized human evidence establishing recovery, musculoskeletal, or gastrointestinal benefit. The body of work is cell and animal injury models, and our profile states that the human mechanism is unestablished.

Proposed nitric-oxide, angiogenesis, and tissue-repair pathways come largely from preclinical work. Real biology, unfinished translation.

We cover the compound in depth in what BPC-157 is.

So the two failure modes differ, which is worth knowing:

BPC-157 studies the right molecule and hasn't reached humans.

TB-500 points at human studies that were run on something else.

Of the two problems, the second is harder to spot and more misleading.

The stack question

They're bundled constantly, usually for "synergy."

No trial established that combining them does anything. There's no adequate human data for either one alone, which means there is certainly none for the pair.

Combining two compounds with unknown individual effects doesn't average out the uncertainty. It multiplies the number of things you can't account for, and it makes any outcome uninterpretable, good or bad.

The pairing is a commercial pattern. Bundles raise order value, and these two are marketed for overlapping purposes, so they get sold together. That's the whole explanation.

Advertising either as an established recovery treatment is the kind of unsupported health claim regulators police.²

The testing gap is the practical problem

Between them these two are listed by 43 vendors in our price market, which is more than any other pair we track.

Our testing ledger holds nine published lab records for both compounds combined. Five for BPC-157, four for TB-500.³

Clean material in every record, and every single vial over its labelled dose.

Nine samples cannot characterise what 43 storefronts ship. The two most-sold repair peptides on the market are also among the least documented, and that combination is the actual risk rather than anything about the molecules.

One more caution when a vendor shows you a certificate: identical lab values appear under multiple vendor names in our ledger, so counting sellers with testing overstates how much independent testing exists. See how to evaluate a peptide vendor.

Where this leaves the comparison

The comparison people want is which one heals better. That question requires human outcome data, and there isn't any for either.

What can be said:

Both are unapproved, and both sit in our lowest evidence tier alongside GHK-Cu and MOTS-c.

TB-500 has the worse evidence situation, because the research usually cited for it studied a different molecule, and no human exposure data has been identified for the fragment itself.

Both are barely tested in the supply, nine records against 43 sellers.

Neither is a decision the evidence can make for you, which means the decision rests entirely on your own tolerance for acting without it.

That's not a hedge. Saying clearly that the evidence does not exist is the most definitive statement available, and it's more useful than a ranking built on nothing.

Profiles with graded outcomes and sources: BPC-157 and TB-500.